Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6087
Abstract: Background: ERBB2 (HER2) insertions and point mutations are oncogenic drivers in non-small cell lung cancer (NSCLC) and now has approved targeted therapy for this patient population. Here, we present the landscape of ERBB2 genetic alterations…
read more here.
Keywords:
mutation landscape;
mutation mutation;
landscape oferbb2;
mutation ... See more keywords